Adial Pharmaceuticals Inc (ADIL) is a publicly traded, clinical-stage biopharmaceutical company that is committed to the development of advanced therapies for illnesses associated with addictions and other related disorders. The company’s primary product candidate, AD04, is a genetically targeted therapeutic agent being developed for the treatment of Alcohol Use Disorder (AUD).
Headquartered in Charlottesville, Virginia, the company operates heavily in the healthcare sector and was founded by Bankole A. Johnson in 2010. Since then, it has been dedicated to creating solutions through the advancement of medication aimed at fighting addiction. This focus is relatively unprecedented in the pharmaceutical industry, establishing Adial Pharmaceuticals as an innovator in the healthcare field.
The centerpiece of the Adial portfolio, AD04, uses a precision medicine approach to treat AUD. It does so by reducing the craving for alcohol in certain populations, thus providing a promising treatment. The drug was developed based upon the founder's discovery- a genetic biomarker- which predicted the response to the drug in a large clinical trial of 283 patients.
Adial Pharmaceuticals has demonstrated its commitment to clinical excellence, scientific innovation and patient welfare. This dedication has earned the company several designations from the U.S. Food and Drug Administration (FDA), such as the Fast Track designation. It has also led to various strategic partnerships and collaborations with other leading healthcare and research institutions.
From raising millions in public offerings to conducting clinical trials across numerous countries, the company continues to make significant strides in its mission to transform the landscape of addiction treatments. Despite facing challenges that come with developing highly-specialized, cutting-edge treatments, Adial remains undeterred in its pursuit of therapies that address addiction on a genetic level, thereby offering hope to patients who previously had limited or no treatment options.
As of 2020, the company has been pushing ahead with its innovative pipeline, including initiating a Phase 3 clinical trial of AD04 in Scandinavia. These strides show Adial's commitment to producing products that fulfill the unmet medical needs of societies worldwide.
In summary, Adial Pharmaceuticals Inc (ADIL) is a pioneering biopharmaceutical company committed to advancing the treatment of addiction through scientifically driven innovation. The company’s unique approach, held up by significant scientific research and discovery, has positioned it as a leader in its field, promising a more progressive future in the battle against Alcohol Use Disorder (AUD) and other addictions.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Adial Pharmaceuticals (ADIL) reported a wider net loss of $52.0M for Q2 2026, with a loss per share of -$11.25, reflecting the high costs of clinical-stage drug development. Despite these deepening losses, analysts maintain a positive outlook with 5 buy ratings and 2 hold ratings. The company continues to advance its pipeline in addiction medicine, relying on funding as it has no product sales revenue yet.
Adial Pharmaceuticals (ADIL) reported a wider net loss of $52.0M for Q2 2026, with a loss per share of -$11.25, reflecting the capital-intensive nature of its clinical-stage drug development. Despite the increased losses, analysts maintain a positive outlook with 5 buy ratings and 2 hold ratings. The company continues to advance its pipeline in addiction medicine without current product sales.
Adial Pharmaceuticals (ADIL) reported a net loss of $52.0 million for the second quarter ended June 30, 2026, primarily due to the acquisition of Azora Therapeutics. The company ended the quarter with $28.7 million in cash and plans to file an IND for AT177, a drug for ulcerative colitis, in the first half of 2027. Insider trading data shows recent purchases by CAPITAL LP COASTLANDS, and institutional holdings reveal mixed activity among hedge funds.
Adial Pharmaceuticals announced its Q2 2026 financial results and provided a business update, highlighting the acquisition of Azora Therapeutics and its lead program AT177 for ulcerative colitis. The company closed an initial $32 million tranche of a private placement and reported $28.7 million in cash and cash equivalents, which is expected to fund operations into the second half of 2027. Adial Pharmaceuticals has shifted its strategic focus to inflammatory diseases, with plans to advance AT177 into clinical trials in 2027.
Adial Pharmaceuticals announced its second quarter 2026 financial results, highlighting the acquisition of Azora Therapeutics and its lead ulcerative colitis drug, AT177. The company secured an initial $32 million in financing and plans to advance AT177 into clinical trials in 2027, focusing on its targeted delivery approach for ulcerative colitis. Despite a net loss of $52.0 million due to acquisition-related expenses, Adial Pharmaceuticals believes its current cash and equivalents will fund operations into the second half of 2027.